Results 31 to 40 of about 1,128,358 (233)
Vaccines, Vaccination, and Vaccinology [PDF]
The Journal of Infectious Diseases, 2003 Although the demonstration in 1796 by Edward Jenner that vaccinia virus could protect against smallpox was epochal, he was following the path opened by the ancients who had used the smallpox virus itself in the practice of variolation. The work of Louis Pasteur on chicken cholera opened the way to vaccine development in the laboratory.
openaire +3 more sources
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
Going beyond the individual: How state-level characteristics relate to HPV vaccine rates in the United States [PDF]
, 2019 Background The human papillomavirus (HPV) vaccine is an underutilized cancer control practice in the United States. Although individual contextual factors are known to impact HPV vaccine coverage rates, the impact of macro-level elements are still ...
Brownson, Ross C +3 more
core +2 more sources
Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting [PDF]
, 2020 Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England.
Kinyanjui, Timothy +5 more
core +1 more source
Molecular Oncology, EarlyView.CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan +6 more
wiley +1 more source
, 2018 Human Papilloma virus has been related not only to 98% of cervical cancers but also to mouth and throat cancers. There is a vaccine that prevents contraction of this virus: HPV vaccine.
vivas, alejandra
core +1 more source
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]
, 2019 Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I. +5 more
core +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
, 2007 Vietnam currently produces an orally administered, bivalent (O1 and O139) killed whole-cell vaccine and is the only country in the world with endemic cholera to use an oral cholera vaccine in public health practice.
Anh, Dang Duc +13 more
core +1 more source
Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania. [PDF]
, 2012 BACKGROUND: Cervical cancer is the leading cause of female cancer-related deaths in Tanzania. Vaccination against human papillomavirus (HPV) offers a new opportunity to control this disease.
Quentin, Wilm +9 more
core +5 more sources